Q3 2016 13F Holders as of 30 Sep 2016
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
28,646,674
-
Shares change
-
-127,982
-
Total reported value, excl. options
-
$464,359,406
-
Value change
-
-$1,083,385
-
Put/Call ratio
-
12.14%
-
Number of buys
-
32
-
Number of sells
-
-34
-
Price
-
$16.21
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2016
86 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2016.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28,646,674 shares
of 104,661,494 outstanding shares and own 27.37% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), JPMORGAN CHASE & CO (3,267,701 shares), FRANKLIN RESOURCES INC (3,107,279 shares), NQ HCIF GP, Ltd. (3,096,650 shares), WELLINGTON MANAGEMENT GROUP LLP (2,413,340 shares), Bank of New York Mellon Corp (1,923,108 shares), Arrowpoint Asset Management, LLC (1,823,214 shares), Polar Capital LLP (1,319,871 shares), BlackRock Fund Advisors (1,317,731 shares), and VANGUARD GROUP INC (811,823 shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.